AIMOVIG®▼ IN THE REAL WORLD

Webinar:  January 21st 2021, 5pm-6.30pm

Speaker: Professor Stewart Tepper, Geisel School of Medicine, Dartmouth

 

Legal Category: POM

Marketing Authorisation Holder: Novartis Europharm Ltd, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

Marketing  Authorisation  Numbers: EU/1/18/1293/001006

Full prescribing information is available upon request from: 

Novartis Ireland Limited, Vista Building, Elm Park Business Campus, Merrion Road, Dublin 4

Ireland, Tel: + 353 1 220 4100 or at www.medicines.ie


This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: drugsafety.dublin@novartis.com or by calling 01 2080 612.


This is a promotional meeting for Healthcare Professionals only and is organised, funded and developed by Novartis Ireland Ltd. The content will include reference to Novartis medicines relevant to the agenda topics.

IE02/AIM20-001d Date of preparation: October 2020